Class: Urinary Antispasmodic
Dosage Forms. Extended-Release Tablet: 7.5 mg, 15 mg
Common FDA Label Indication, Dosing, and Titration.
1. Overactive bladder: 7.5 mg po daily, may titrate to 15 mg po daily
Off-Label Uses. None
MOA. Darifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of the urinary bladder smooth muscle and stimulation of salivary secretion.
Drug Characteristics: Darifenacin
Medication Safety Issues: Darifenacin
Drug Interactions: Darifenacin
Adverse Reactions: Darifenacin
Efficacy Monitoring Parameters. Resolution of clinical signs of bladder spasticity, incontinence, urinary urgency and frequency.
Toxicity Monitoring Parameters. Severe anticholinergic effects (dry mouth, cognitive impairment, constipation, vision changes).
Key Patient Counseling Points. This drug may cause anticholinergic effects including constipation, urinary retention, blurred vision, constipation, dyspepsia, or xerostomia. Heat prostration (due to decreased sweating) can occur when used in a hot environment.
Clinical Pearls. May note decline in cognitive function, especially in elderly patients.